Trial Profile
Efficacy and safety of sofosbuvir and daclatasvir in hemodialysis patients with chronic hepatitis c infection.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jan 2018
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 19 Jan 2018 New trial record